LogicBio Therapeutics (NASDAQ: LOGC)
Q2 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | (EXPECTED)2022-08-19 | ||||||
REV |
Q1 2022 | Est. | Actual | Surprise | ||||
---|---|---|---|---|---|---|---|
EPS | -0.280 | -0.200 | 0.0800 | ||||
REV | 900.000K | 2.816M | 1.916M |
Date | Analyst Firm | Analyst Name | Action | Rating | Action Price | Prior Price | Target |
---|
You can purchase shares of LogicBio Therapeutics (NASDAQ: LOGC) through any online brokerage.
Other companies in LogicBio Therapeutics’s space includes: Allena Pharma (NASDAQ:ALNA), Immuron (NASDAQ:IMRN), Biocept (NASDAQ:BIOC), Midatech Pharma (NASDAQ:MTP) and Calithera Biosciences (NASDAQ:CALA).
The latest price target for LogicBio Therapeutics (NASDAQ: LOGC) was reported by Chardan Capital on Tuesday, May 17, 2022. The analyst firm set a price target for 4.00 expecting LOGC to rise to within 12 months (a possible 612.63% upside). 7 analyst firms have reported ratings in the last year.
The stock price for LogicBio Therapeutics (NASDAQ: LOGC) is $0.5613 last updated Today at August 8, 2022, 4:23 PM UTC.
There are no upcoming dividends for LogicBio Therapeutics.
LogicBio Therapeutics’s Q2 earnings are confirmed for Friday, August 19, 2022.
There is no upcoming split for LogicBio Therapeutics.
LogicBio Therapeutics is in the Health Care sector and Biotechnology industry. They are listed on the NASDAQ.